Intellia Therapeutics Stock News

The FDA has granted Orphan Drug Designation to an Intellia Therapeutics (NTLA) CRISPR treatment for acute myeloid leukemia.

The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a significant 31% fall in a month while it is down 34% over the las

Intellia Therapeutics <> was upgraded by Brookline Capital Management to Buy from Hold with a $91 price target.Brookline analyst Leah Cann said the patent risk is unchanged, but…

Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics showed an EPS of $1.09,

The Harbor Disruptive Innovation ETF takes a broad approach to stock selection.

A recent legal ruling raises an important question about Intellia Therapeutics' path forward.

Sometimes yes, but the risks are similar in magnitude too.

A recent legal ruling raises an important question about Intellia Therapeutics' path forward.

The Cambridge-based biotechnology company fell by the most in more than five years the US Patent and Trademark Office invalidated a key patent Intellia licensed.

Over the past 3 months, 4 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understan

The decision is a setback for Intellia Therapeutics, Crispr Therapeutics, and Caribou Biosciences, and a win for Editas Medicine and Beam Therapeutics.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine, Inc. (NASDAQ: EDIT) sai

CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutic

CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the first patient has been dosed with NTLA-5001, the company’s ex vivo CRISPR/Cas9 genome editing candidate for the treatment of acute myeloid leukemia (AML). NTLA-5001 is an autologous T cell receptor (TCR)-T cell therapy designed to target the Wilms’ Tumor (WT1) antigen, which is found in AML and many other hematologic and solid tumors. It is the company’s first ex vivo candidate developed using Intellia’s advanced lipid nanoparticle cell engineering platform, designed to improve cell performance as compared to traditional ex vivo delivery technologies.